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A total synthesis of paroxetine is reported, with a diastereo-
selective and diastereoconvergent cobalt-catalysed sp3–sp2
coupling reaction involving a 3-substituted 4-bromo-N-Boc-
piperidine (Boc = tert-butoxycarbonyl) substrate as a key
Introduction
Recent years have seen a marked rise in the use of
cheaper transition metals for catalytic C–C bond formation.
Iron and cobalt are particularly attractive for large-scale
metal catalysis as they have far lower toxicities than nickel
or palladium. Recent demonstrations of their ability to cat-
alyse the union of aryl Grignard reagents with unactivated
secondary alkyl halides represent a significant advance in
the synthetic potential of these emerging protocols.[1,2]
To date, investigations into the diastereoselectivity of
such cross-couplings are limited.[3] With 3- and 4-substi-
tuted bromocyclohexane derivatives, a number of reports
have demonstrated the preferential incorporation of the
“nucleophilic” component into the less encumbered equato-
rial position in iron-catalysed cross-coupling reactions [e.g.,
Scheme 1 (i)].[3a] Similar observations have been made for
the analogous cobalt-catalysed reactions, with bicyclohept-
anes exo-3 and endo-3 both giving exo-4 when treated with
PhMgBr [Scheme 1 (ii)].[3b]
Mechanistically, the stereochemical outcome has been
explained by the involvement of a radical intermediate, as
seen in the proposed mechanism shown in Scheme 2.[3c,4]
Ferrate complexes (I) have been proposed as the reactive
species when the Grignard reagent involved is unable to un-
dergo β-hydride elimination. Indeed, such complexes have
been prepared by Fürstner et al., who showed that they
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step. A 9:1 diastereoselectivity was obtained, while a control
experiment involving a conformationally locked 3-substi-
tuted 4-bromo-tert-butyl cyclohexane ring proceeded with
essentially complete stereoselectivity.
Scheme 1. Diastereoconvergent coupling reactions;[3a,3b] a) FeCl3
(5 mol-%), ArMgBr (1.3 equiv.), TMEDA (1.2 equiv.), THF, room
temp., 30 min; b) CoCl2 (5 mol-%), PhMgBr (1.2 equiv.), (R,R)-
N,N,N,N-tetramethyl-1,2-cyclohexanediamine (6 mol-%), THF,
25 °C, 15 min.
efficiently catalyse cross-coupling reactions.[5] An alkyl radi-
cal (II) can then be generated by reaction of the reduced
ferrate complex with the alkyl bromide.[6] Recombination of
the alkyl radical with the metal complex to give III, fol-
lowed by reductive elimination, would liberate the cross-
coupling product. Similar mechanisms have been proposed
for the cobalt-catalysed allylation of alkyl halides,[3b,7] as
well as for a cobalt-catalysed tandem cyclisation and aryl-
ation reaction.[8] The configurational lability of the radical
intermediate (II) nicely accounts for the formation of the
Scheme 2. Proposed mechanism for the cross-coupling reaction.[3–8]
SET = single-electron transfer.
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Scheme 3. Retrosynthetic analysis. Boc = tert-butoxycarbonyl.
most stable diastereoisomer (e.g., trans-2, exo-4). A late
transition state for the reductive elimination step has also
been invoked to explain the bias towards production of the
thermodynamic product.[1,3]
In this paper, we report a successful application of this
diastereoconvergent cross-coupling methodology in a short
synthesis of paroxetine 5 (Paxil®, Scheme 3).[9] Paroxetine
is a potent inhibitor of serotonin reuptake, and is widely
prescribed for the treatment of depression, obsessive-com-
pulsive disorder, panic disorder, social and anxiety disorder,
and post-traumatic stress disorder.[10]
Results and Discussion
Our retrosynthetic analysis is shown in Scheme 3, with
secondary bromide 6 as a key intermediate for the introduc-
tion of the aryl residue. As the coupling is expected to be
diastereoconvergent, our strategy allows for its production
as a mixture of diastereomers. Consequently, the synthesis
of 6 can be envisioned from commercially available 8 using
standard chemistry.
A literature survey revealed that N-protected 4-bromopi-
peridine derivatives have been used as substrates in iron/
cobalt-catalysed coupling reactions,[11] yet none of the ex-
amples reported featured α-alkyl substitution. Moreover,
cross-couplings on six-membered rings with α-alkyl substit-
uents have little precedent.[12,13] Hence, both the reactivity
and the stereochemical outcome of our key step would be
instructive, given that substituted piperidines are ubiquitous
in natural products and medicines.[9j,14,15]
The synthesis of bromide precursor 6 was readily ac-
complished in three steps from known diol 7 (Scheme 4).[16]
Regioselective tosylation of 7 (dr 58:42) proceeded in good
yield using triethylamine (2.1 equiv.) as the base. Introduc-
tion of the sesamol group with Cs2CO3 in DMF gave ad-
duct 10 in 51% yield. This yield improved to 76 % when a
toluene solution of 9 and sesamol was exposed to aqueous
NaOH using tetrabutylammonium hydroxide as phase-
transfer catalyst. Finally, conversion of alcohol 10 into
bromide 6 was achieved in 65% yield through the action of
bromotriphenylphosphonium bromide. Bromination of the
electron-rich sesamol ring was never observed with this rea-
gent, in contrast to related procedures using triphenylphos-
phine and bromine, where it proved to be a minor side-
reaction (10% yield).
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Scheme 4. Synthesis of the cross-coupling precursor; DMAP = 4-
(dimethylamino)pyridine.
We were now in a position to examine our key cross-
coupling step with p-fluorophenylmagnesium bromide. For
completeness, we decided to separate the diastereoisomers
of 6 in order to rigorously establish diastereoconvergence
for each stereoisomer. To that end, the cis and trans dia-
stereomers of alcohol 10 were separated by chromatog-
raphy, then each was brominated to give trans- and cis-6,
respectively. However, it proved more convenient to sepa-
rate cis and trans bromides 6 by selective precipitation from
hexane/Et2O.
The optimisation studies for the cross-coupling of brom-
ides 6 with 4-fluorophenylmagnesium bromide are summa-
rised in Table 1. Preliminary studies with iron(III) chloride/
TMEDA (N,N,N,N-tetramethylethylenediamine; Table 1,
entries 1 and 2) and (FeCl3)2(TMEDA)3[4] (Table 1, entry 3)
mainly returned unreacted starting material. However, a
switch to iron(III) acetylacetonate (acac) in combination
with TMEDA and hexamethylenetetramine (HMTA)[4]
showed some promise, with cis-6 giving a 16% yield of cou-
pling product 11 as a 78:22 mixture of trans/cis isomers
(Table 1, entry 4). The same reaction using trans-6 gave a
lower yield, with a similar ratio of trans- and cis-11 (Table 1,
entry 5). Hence, these results demonstrate the expected dia-
stereoconvergence.
Increasing the temperature and the amount of Grignard
reagent used led to a modest increase in yield (Table 1, en-
try 6), but the product mixture now contained significant
levels of elimination product 12. It is unclear whether 12
was formed by a reductive elimination process, or by degra-
dation of the starting material. The formation of thermody-
Total Synthesis of ()-Paroxetine
Table 1. Investigation of the cross-coupling step.
Entry dr of 6[a,b] Catalyst (equiv.) Additive (equiv.) ArMgBr Conditions dr of 11[a,c] Ratio 6:11:12[d] Yield [%][e]
[equiv.]
1 1:99 FeCl3 (0.05) TMEDA[f] (1.2) 1.2[g] THF, 0.5 h, 0 °C – – 1
2 59:41 FeCl3 (0.05) TMEDA (1.2) 1.2[g] THF, 18 h, 0 °C to r.t. – 72:1:27 1
3 99:1 [(FeCl3)2(TMEDA)3] – 1.3[g] THF, 0.5 h, r.t. – – 0
(0.05)
4 1:99 Fe(acac)3 (0.05) TMEDA (0.1), 1.3[g] THF, 78:22 67:32:1 16
HMTA[h] (0.05) 0.5 h, 0 °C
5 99:1 Fe(acac)3 (0.05) TMEDA (0.1), 1.3[g] THF, 79:21 73:27:1 7
HMTA (0.05) 4 h, 0 °C
6 11:89 Fe(acac)3 (0.1) TMEDA (0.1), 2.0[g] THF, 77:23 46:45:9 20
HMTA (0.05) 23 h, r.t.
7 1:99 Fe(acac)3 (0.05) TMEDA (0.1), 1.3[g] Et2O, 74:26 69:23:8 10
HMTA (0.05) 4 h, 0 °C
8 1:99 Fe(acac)3 (0.1) NMP (5.8) 3.2[g] THF, 7 h, 0 °C 66:34 85:10:5 3
9 30:70 bmim-FeCl4 (0.05) – 1.5[i] MeTHF, 68:32 67:15:18 12
0.5 h, 0 °C to r.t.
10 99:1 Co(acac)3 (0.05) TMEDA (0.05) 1.1[g] THF, 83:17 69:25:6 20
40 min, 0 °C
11 1:99 Co(acac)3 (0.05) TMEDA (1.0) 2.1[g] THF, 87:13 46:53:1 31
3 h, 0 °C
12 99:1 Co(acac)3 (0.05) TMEDA (0.05) 2.0[g] Et2O, 79:21 71:29:1 n.d.
1 h, 0 °C
13 99:1 Co(acac)3 (0.05) TMEDA (0.5), 2.0[i] MeTHF, 89:11 45:50:5 43
HMTA (0.1) 2 h, 0 °C to r.t.
14 99:1 Co(acac)3 (0.1) TMEDA (0.5), 2.0[i] MeTHF, 90:10 15:80:5 77
HMTA (0.5) 2 h, 0 °C to r.t.
15 99:1 Co(acac)3 (0.1) TMEDA (0.5), 2.0[i] MeTHF, 88:12 43:51:6 26
HMTA (0.5) 2 h, –5 °C
16 30:70 Co(acac)3 (0.1) TMEDA (0.5), 2.0[j] MeTHF, 88:12 58:29:14 26
HMTA (0.5) 2 h, 0 °C to r.t.
17 99:1 Co(acac)3 (0.1) bpy[k] (0.5), 2.0[i] MeTHF, 71:29 89:8:3 4
HMTA (0.5) 2 h, 0 °C to r.t.
18[l] 30:70 Co(acac)3 (0.1) TMEDA (0.5), 2.0[i] MeTHF, 88:12 11:88:1 76
HMTA (0.5) 5 h, 0 °C to r.t.
[a] trans/cis. [b] Determined by 1H NMR spectroscopy. [c] Determined by 19F NMR spectroscopy of the crude material. [d] Determined
by 1H NMR spectroscopy of the crude material. [e] Isolated yield of 11. [f] N,N,N,N-Tetramethylethylenediamine. [g] Added as a 1 m
solution in THF. [h] Hexamethylenetetramine. [i] Added as a 1 m solution in MeTHF. [j] Added as a 0.5 m solution in MeTHF. [k] 2,2-
Bipyridine. [l] Reaction carried out on 1.05 g (2.53 mmol) of 6.
namically more stable alkene 12 as the only observed elimi-
nation product suggests that the latter process predomi-
nates. In the iron-catalysed coupling reaction between tolyl-
magnesium bromide and 5-phenyl-1-bromopentane, Na-
gano and Hayashi described that the reaction was improved
by using diethyl ether as the solvent instead of THF.[17] Un-
fortunately, in our case, switching the solvent to diethyl
ether (Table 1, entry 7), lowered both the yield and the
selectivity, as did the use of N-methyl-2-pyrrolidone (NMP)
in combination with THF (Table 1, entry 8).[18] The pro-
cedure of Bica and Gaertner, i.e., the use of the ionic liquid
bmim-FeCl4 as an iron source, was also investigated,[11b] but
this too gave low yields and poor selectivities (Table 1, en-
try 9).
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At this juncture we decided to examine the use of more
reactive CoIII catalysts. Pleasingly, our first reaction with
Co(acac)3/TMEDA,[19] gave 11 in 20% yield (Table 1, en-
try 10) with an improved selectivity for trans-11. The yield
was elevated to 31 % by using a molar equivalent of
TMEDA and 2.1 equiv. of ArMgBr (Table 1, entry 11). As
with the iron-catalysed examples, the selectivity dropped
when diethyl ether was used as solvent (Table 1, entry 12),
although it improved slightly when cat. HMTA was used in
MeTHF (Table 1, entry 13).
A step change in performance was noted when we em-
ployed 10 mol-% of Co(acac)3 with a combination of
TMEDA and HMTA as additives in MeTHF (Table 1, en-
try 14).[4] Under these conditions, the desired product (i.e.,
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11) was obtained in 77% yield with a trans/cis ratio of 90:10
(Table 1, entry 14). The yield dropped significantly when
the reaction was carried out at lower temperature (Table 1,
entry 15), though the same product ratio was obtained.
Attempts to increase the selectivity by adding a more dilute
solution of the Grignard reagent (Table 1, entry 16) or by
substituting TMEDA with bpy (Table 1, entry 17) were also
unsuccessful. Pleasingly, using our optimised conditions on
a gram scale (Table 1, entry 18) with a diastereoisomeric
mixture of bromide 6 gave paroxetine precursor 11 as a sep-
arable 88:12 mixture of trans and cis diastereomers in 76%
yield. Comparison between Table 1, entries 14 and 18 again
confirmed the diastereoconvergence of the process.
Although the diastereoselectivity was satisfactory, it did
not match the levels obtained with locked cyclohexyl deriv-
ative cis-1 (i.e., 96:4; Scheme 1). As a control experiment,
we decided to prepare cyclohexyl analogue cis-13 and test
it, using our optimised conditions, in a cross-coupling reac-
tion with (4-fluorophenyl)magnesium bromide (Scheme 5).
Surprisingly, it gave trans-14 as the sole reaction product,
as judged by 1H and 19F NMR spectroscopic analysis. The
strong conformational lock imposed by the tert-butyl group
provides a possible explanation for the improved diastereo-
selectivity obtained in this system compared to the N-Boc-
piperidine substrates (see Table 1). However, it is also plaus-
ible that N-Boc chelation prior to the reductive elimination
provides additional stabilisation for an axial organocobalt
intermediate.
Scheme 5. Control experiment with a conformationally locked cy-
clohexane derivative.
Finally, the synthesis of ()-paroxetine was completed by
removal of the Boc protecting group (Scheme 6). Following
Jacobsen’s conditions,[20a] our target 5·HCl was obtained in
Scheme 6. Completion of the synthesis.
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quantitative yield as off-white crystals by recrystallisation
from 2-propanol.[20b] All spectroscopic data matched litera-
ture values.[20b]
Conclusions
In conclusion, we have developed a short route to ()-
paroxetine using a cobalt-mediated cross-coupling reaction
to construct the 3,4-disubstituted piperidine scaffold. The
key step is notable for being diastereoconvergent, consistent
with reported mechanistic studies. Importantly, for bromo-
cyclohexane 13, the diastereoselectivity was essentially com-
plete, whereas for N-Boc-piperidine 6 it dropped to 9:1. No-
tably, our synthesis of ()-paroxetine 5 is unique in that the
p-fluorophenyl ring is introduced in the penultimate step.
An enantioselective total synthesis is currently under inves-
tigation.
Experimental Section
N-Boc-4-hydroxy-3-(tosyloxymethyl)piperidine (9): A solution of p-
toluenesulfonyl chloride (1.26 g, 6.61 mmol, 1.1 equiv.) in anhy-
drous CH2Cl2 (11 mL) was added to a solution of N-Boc-3-
hydroxymethyl-4-piperidol 7 (1.39 g, 6.01 mmol, 1 equiv.), dry tri-
ethylamine (1.76 mL, 12.62 mmol, 2.1 equiv.), and DMAP (73 mg,
0.60 mmol, 0.1 equiv.) in dry CH2Cl2 (22 mL) under argon at room
temp. The reaction mixture was stirred at room temp. After 23 h,
water (36 mL) was added, and the product was extracted with
CH2Cl2 (3 36 mL). The combined organic layers were washed
with brine (36 mL), dried with magnesium sulfate, and concen-
trated under reduced pressure. The crude mixture was purified by
column chromatography (petroleum ether/acetone, from 80:20 to
70:30) to give 9 [1.79 g, 77%, 67:33 dr (trans:cis)] as a colourless
oil. The two diastereoisomers could be separated by HPLC
(hexane/acetone 80:20).
Data for trans diastereoisomer: Rf (hexane/acetone, 80:20): 0.18. IR
(neat): ν˜ = 3424 (br. w), 2975 (w), 2929 (w), 1694 (m), 1669 (m),
1428 (br. m), 1175 (s), 959 (br. w) cm–1. 1H NMR (400 MHz, [D6]-
DMSO, 343 K): δ = 7.78 (d, J = 8.2 Hz, 2 H, 9-H or 10-H), 7.49
(d, J = 8.1 Hz, 2 H, 9-H or 10-H), 4.24 (dd, J = 10.0, 3.8 Hz, 1 H,
7-H), 3.98 (dd, J = 10.0, 8.1 Hz, 1 H, 7-H), 3.86 (br. ddd, J = 13.4,
4.0, 1.8 Hz, 1 H, 2eq-H), 3.78 (dtd, J = 13.4, 4.3, 1.9 Hz, 1 H, 6eq-
H), 3.34 (td, J = 9.5, 4.4 Hz, 1 H, 4ax-H), 2.77 (ddd, J = 13.5, 11.6,
3.0 Hz, 1 H, 6ax-H), 2.57 (dd, J = 13.1, 10.5 Hz, 1 H, 2ax-H), 2.43
(s, 3 H, 12-H), 1.74 (dq, J = 12.9, 3.7 Hz, 1 H, 5eq-H), 1.52–1.64
(m, 1 H, 3-H), 1.39 (s, 9 H, 15-H), 1.24 (dddd, J = 12.9, 11.6, 10.0,
4.5 Hz, 1 H, 5ax-H) ppm. 13C NMR + DEPT 135 (100 MHz, [D6]-
DMSO, 343 K): δ = 153.6, 144.5 (C, C-8, C-13), 132.4 (C, C-11),
129.8, 127.1 (CH, C-9, C-10), 78.5 (C, C-14), 69.7 (CH2, C-7), 66.4
(CH, C-4), 43.6 (CH2, C-2), 42.9 (CH, C-3), 41.5 (CH2, C-6), 33.2
(CH2, C-5), 27.7 (CH3, C-15), 20.7 (CH3, C-12) ppm. MS (ES+):
m/z = 408.2 [M + Na]+. HRMS (ES+): calcd. for C18H27NNaO6S+
[M + Na]+ 408.1451; found 408.1454.
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Data for cis diastereoisomer: Rf (hexane/acetone, 80:20): 0.21. IR
(neat): ν˜ = 3425 (br. w), 2975 (w), 2927 (w), 1694 (m), 1670 (m),
1428 (br. m), 1175 (s), 959 (br. w) cm–1. 1H NMR (400 MHz, [D6]-
DMSO, 363 K): δ = 7.77 (d, J = 8.3 Hz, 2 H, 9-H or 10-H), 7.48
(d, J = 8.1 Hz, 2 H, 9-H or 10-H), 4.13 (dd, J = 9.9, 5.2 Hz, 1 H,
7-H), 3.92 (dd, J = 9.9, 9.4 Hz, 1 H, 7-H), 3.84 (q, J = 4.0 Hz, 1
H, 4eq-H), 3.49 (dd, J = 13.1, 3.8 Hz, 1 H, 2eq-H), 3.43 (dt, J =
13.3, 4.8 Hz, 1 H, 6eq-H), 3.23 (ddd, J = 13.3, 7.6, 5.8 Hz, 1 H, 6ax-
H), 3.04 (app. dd, J = 12.9, 9.3 Hz, 1 H, 2ax-H), 2.44 (s, 3 H, 12-
H), 1.87 (tdt, J = 9.4, 5.2, 3.8 Hz, 1 H, 3ax-H), 1.46–1.53 (m, 2 H,
2 5-H), 1.39 (s, 9 H, 15-H) ppm. 13C NMR + DEPT 135 (100 MHz,
[D6]DMSO, 343 K): δ = 153.7, 144.4 (C, C-8, C-13), 132.5 (C, C-
11), 129.8, 127.1 (CH, C-9, C-10), 78.3 (C, C-14), 69.5 (CH2, C-7),
63.5 (CH, C-4), 40.7 (CH2, C-2), 39.7 (CH, C-3), 38.7 (CH2, C-6),
31.4 (CH2, C-5), 27.7 (CH3, C-15), 20.7 (CH3, C-12) ppm. MS
(ES+): m/z = 408.2 [M + Na]+. HRMS (ES+): calcd. for
C18H27NNaO6S+ [M + Na]+ 408.1451; found 408.1458.
N-Boc-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidin-4-ol (10):
NaOH (50 % aq.; 2.9 mL) was added to a mixture of N-Boc-4-
hydroxy-3-[(tosyloxy)methyl]piperidine 9 (cis and trans; 591 mg,
1.53 mmol, 1 equiv.), tetra-n-butylammonium hydroxide (1.0 m in
H2O; 77 μL, 0.08 mmol, 0.05 equiv.), and sesamol (233 mg,
1.69 mmol, 1.1 equiv.) in toluene (5.7 mL). The reaction mixture
was stirred at 70 °C. After 25 h, the aqueous and organic phases
were separated. The aqueous phase was extracted with EtOAc (3
20 mL), then the combined organic phases were dried with magne-
sium sulfate and concentrated under reduced pressure. The crude
mixture was purified by column chromatography (petroleum ether/
EtOAc, 60:40) to give 10 (412 mg, 76%) as a yellow oil. The two
diastereoisomers were separated by HPLC (hexane/EtOAc, 60:40)
to give the trans diastereoisomer (280 mg, 52%) as a pale yellow
oil, and the cis diastereoisomer (128 mg, 24%) as a colourless
oil.
Data for trans diastereoisomer: Rf (hexane/EtOAc, 50:50): 0.27. IR
(neat): ν˜ = 3049 (br. w), 2975 (w), 2927 (br. w), 1686 (br. s), 1670
(br. s), 1489 (s), 1182 (br. s), 1038 (m) cm–1. 1H NMR (400 MHz,
[D6]DMSO, 363 K): δ = 6.77 (d, J = 8.5 Hz, 1 H, 13-H), 6.58 (d,
J = 2.5 Hz, 1 H, 9-H), 6.38 (dd, J = 8.5, 2.5 Hz, 1 H, 14-H), 5.93
(s, 2 H, 11-H), 4.56 (d, J = 5.4 Hz, 1 H, OH), 4.12 (dd, J = 9.9,
3.7 Hz, 1 H, 7-H), 4.00 (ddd, J = 13.3, 4.3, 1.9 Hz, 1 H, 2eq-H),
3.84 (dd, J = 10.0, 8.0 Hz, 1 H, 7-H), 3.81 (dtd, J = 13.3, 4.3,
1.8 Hz, 1 H, 6eq-H), 3.50 (tdd, J = 9.2, 5.3, 4.8 Hz, 1 H, 4ax-H),
2.88 (ddd, J = 13.4, 11.1, 3.2 Hz, 1 H, 6ax-H), 2.78 (dd, J = 13.3,
9.9 Hz, 1 H, 2ax-H), 1.81 (dtd, J = 12.9, 4.3, 3.5 Hz, 1 H, 5eq-H),
1.71 (ddddd, J = 9.9, 9.2, 8.0, 4.3, 3.7 Hz, 1 H, 3ax-H), 1.40 (s, 9
H, 17-H), 1.33 (dddd, J = 12.9, 11.1, 9.2, 4.3 Hz, 2 H, 5ax-H) ppm.
13C NMR + DEPT 135 (100 MHz, [D6]DMSO, 343 K): δ = 154.0,
153.7, 147.6, 140.9 (C, C-15, C-8, C-10, C-12), 107.6 (CH, C-13),
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105.9 (CH, C-14), 100.6 (CH2, C-11), 97.7 (CH, C-9), 78.3 (C, C-
16), 67.9 (CH2, C-7), 66.9 (CH, C-4), 44.2 (CH2, C-2), 43.2 (CH,
C-3), 41.4 (CH2, C-6), 33.3 (CH2, C-5), 27.7 (CH3, C-17) ppm. MS
(ES+): m/z = 374.2 [M + Na]+. HRMS (ES+): calcd. for
C18H25NNaO6+ [M + Na]+ 374.1574; found 374.1577.
Data for cis diastereoisomer: Rf (hexane/EtOAc, 60:40): 0.24. IR
(neat): ν˜ = 3446 (br. w), 2974 (w), 2928 (w), 1665 (br. m), 1489 (s),
1183 (br. s), 1038 (m) cm–1. 1H NMR (400 MHz, [D6]DMSO,
363 K): δ = 6.77 (d, J = 8.6 Hz, 1 H, 13-H), 6.57 (d, J = 2.5 Hz, 1
H, 9-H), 6.37 (dd, J = 8.6, 2.5 Hz, 1 H, 14-H), 5.93 (s, 2 H, 11-H),
4.56 (br. d, J = 3.5 Hz, 1 H, OH), 3.99 (dd, J = 9.9, 5.3 Hz, 1 H,
7-H), 3.94 (app. t, J = 3.5 Hz, 1 H, 4eq-H), 3.76 (dd, J = 9.6, 8.6 Hz,
1 H, 7-H), 3.58 (br. d, J = 12.6, 3.5 Hz, 1 H, 2eq-H), 3.46 (dt, J =
12.9, 4.9 Hz, 1 H, 6eq-H), 3.32 (m, 1 H, 6-H), 3.20 (m, 1 H, 2-H),
1.96 (m, 1 H, 3-H), 1.51–1.62 (m, 2 H, 5-H), 1.37 (s, 9 H, 17-H)
ppm. 13C NMR + DEPT 135 (100 MHz, [D6]DMSO, 353 K): δ =
154.0, 153.8, 147.6, 140.8 (C, C-15, C-8, C-10, C-12), 107.5 (CH,
C-13), 105.9 (CH, C-14), 100.5 (CH2, C-11), 97.6 (CH, C-9), 78.1
(C, C-16), 67.4 (CH2, C-7), 64.0 (CH, C-4), 41.3 (CH2, C-2), 40.2
(CH, C-3), 38.9 (CH2, C-6), 31.6 (CH2, C-5), 27.7 (CH3, C-17)
ppm. MS (ES+): m/z = 374.2 [M + Na]+. HRMS (ES+): calcd. for
C18H25NNaO6+ [M + Na]+ 374.1574; found 374.1580.
N-Boc-4-bromo-3-{[3,4-(methylenedioxy)phenoxy]methyl}piperidine
(6): A mixture of N-Boc-3-{[3,4-(methylenedioxy)phenoxy]-
methyl}piperidin-4-ol 10 (1.29 g, 3.67 mmol, 1.0 equiv.) and imid-
azole (300 mg, 4.41 mmol, 1.2 equiv.) in dry dichloromethane
(8.5 mL) was cooled to 0 °C. A solution of bromotriphenylphos-
phonium bromide (1.704 g, 4.04 mmol, 1.1 equiv.) in dry CH2Cl2
(9.1 mL) was stirred at room temp. for 15 min, and then added
dropwise to the starting material. The reaction mixture was stirred
in the dark for 24 h at room temp., then it was diluted with water
(25 mL) and extracted with CH2Cl2 (3 70 mL). The organic layer
was dried with sodium sulfate and concentrated under reduced
pressure. The crude mixture was purified by column chromatog-
raphy (petroleum ether/EtOAc, 90:10) to give 6 [1.521 g, 65%,
70:30 dr (cis/trans)] as a colourless oil. The two diastereoisomers
could be separated by selective precipitation of cis-6 from hexane/
diethyl ether (90:10).
Data for trans diastereoisomer: Rf (petroleum ether 40–60 °C/
EtOAc, 90:10): 0.20. IR (neat): ν˜ = 2957 (w), 1698 (m), 1489 (m),
1264 (s), 1184 (br. w), 730 (br. s), 703 (m), 651 (w) cm–1. 1H NMR
(400 MHz, [D6]DMSO, 373 K): δ = 6.78 (d, J = 8.3 Hz, 1 H, 13-
H), 6.60 (d, J = 2.4 Hz, 1 H, 9-H), 6.41 (dd, J = 8.3, 2.4 Hz, 1 H,
14-H), 5.94 (s, 2 H, 11-H), 4.41 (td, J = 9.7, 4.3 Hz, 1 H, 4ax-H),
4.11 (dd, J = 10.1, 3.6 Hz, 1 H, 7-H), 4.05 (ddd, J = 13.6, 4.2,
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2.0 Hz, 1 H, 2eq-H), 3.98 (dd, J = 10.2, 7.0 Hz, 1 H, 7-H), 3.78
(dtd, J = 13.5, 4.4, 1.9 Hz, 1 H, 6eq-H), 2.98–3.09 (m, 2 H, 2-H, 6-
H), 2.28 (dtd, J = 13.2, 4.3, 3.2 Hz, 1 H, 5eq-H), 2.06–2.17 (m, 1
H, 3-H), 1.84–1.97 (m, 1 H, 5-H), 1.42 (s, 9 H, 17-H) ppm. 13C
NMR + DEPT 135 (100 MHz, [D6]DMSO, 353 K): δ = 153.5,
153.5, 147.6, 141.2 (C, C-15, C-8, C-10, C-12), 107.6 (CH, C-13),
106.1 (CH, C-14), 100.6 (CH2, C-11), 97.8 (CH, C-9), 78.7 (C, C-
16), 69.1 (CH2, C-7), 51.6 (CH, C-4), 45.2 (CH2, C-2), 44.1 (CH,
C-3), 43.0 (CH2, C-6), 35.5 (CH2, C-5), 27.6 (CH3, C-17) ppm. MS
(ES+): m/z = 436.1, 438.0 [M + Na]+. HRMS (ES+): calcd. for
C18H2479BrNNaO5+ [M + Na]+ 436.0730; found 436.0733.
Data for cis diastereoisomer: Rf (petroleum ether 40–60 °C/EtOAc,
90:10): 0.17. IR (neat): ν˜ = 2958 (w), 1696 (m), 1489 (m), 1265 (s),
1183 (br. m), 732 (br. s), 702 (m), 650 (w) cm–1. 1H NMR
(400 MHz, [D6]DMSO, 353 K): δ = 6.78 (d, J = 8.6 Hz, 1 H, 13-
H), 6.61 (d, J = 2.5 Hz, 1 H, 9-H), 6.40 (dd, J = 8.6, 2.5 Hz, 1 H,
14-H), 5.94 (s, 2 H, 11-H), 4.86 (app. q, J = 3.2 Hz, 1 H, 4eq-H),
3.81–3.96 (m, 3 H, 2-H, 2 7-H), 3.77 (dt, J = 13.4, 4.2 Hz, 1 H,
6eq-H), 3.21 (ddd, J = 13.8, 10.0, 4.0 Hz, 1 H, 6ax-H), 2.97 (br. dd,
J = 13.1, 10.1 Hz, 1 H, 2ax-H), 1.95–2.17 (m, 3 H, 3-H, 2 5-H),
1.40 (s, 9 H, 17-H) ppm. MS (ES+): m/z = 436.1, 438.2 [M + Na]+.
HRMS (ES+): calcd. for C18H2479BrNNaO5+ [M + Na]+ 436.0730;
found 436.0729.
N-Boc-4-(p-fluorophenyl)-3-[3,4-(methylenedioxy)phenoxymethyl]-
piperidine (11): N-Boc-4-bromo-3-{[3,4-(methylenedioxy)phenoxy]-
methyl}piperidine (6) (1.049 g, 2.53 mmol, 1 equiv.), Co(acac)3
(90 mg, 0.25 mmol, 0.1 equiv.), TMEDA (190 μL, 1.27 mmol,
0.5 equiv.), HMTA (177 mg, 1.27 mmol, 0.5 equiv.), and MeTHF
(5.1 mL) were put into a flame-dried two-necked round-bottomed
flask. The reaction mixture was cooled to 0 °C, then a solution
of 4-fluorophenylmagnesium bromide (1.0 m in MeTHF; 5.1 mL,
5.1 mmol, 2.0 equiv.) was added over 3 h. After the addition was
complete, the reaction mixture was stirred for 1 h at 0 °C, and then
for 1 h at room temp. Then the mixture was quenched with aqueous
HCl (1 m aq.; 7.3 mL). The aqueous layer was extracted with di-
ethyl ether (3 28 mL), and the combined organic layers were
dried with magnesium sulfate and concentrated under reduced
pressure. The crude mixture [88:12 dr (trans:cis)] was purified by
column chromatography (pentane/acetone, 94:6) to give 11
(826 mg, 76%) as a colourless oil, in a mixture with unreacted start-
ing material 6. The mixture was purified by HPLC (pentane/acet-
one, 94:6) to give trans-11 (722 mg, 66%) as a colourless oil, which
solidified on standing and was recrystallised from pentane, and cis-
11 (46 mg, 4%) as a colourless oil.
Data for trans diastereoisomer: Rf (pentane/acetone, 94:6): 0.13,
m.p. 96.0–97.0 °C (pentane). 1H NMR (400 MHz, [D6]DMSO,
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353 K): δ = 7.27 (dd, J = 8.8, 5.6 Hz, 2 H, 16-H), 7.08 (t, J =
8.8 Hz, 2 H, 17-H), 6.70 (d, J = 8.4 Hz, 1 H, 13-H), 6.40 (d, J =
2.5 Hz, 1 H, 9-H), 6.18 (dd, J = 8.6, 2.5 Hz, 1 H, 14-H), 5.90 (s, 2
H, 11-H), 4.30 (ddd, J = 13.1, 4.0, 1.5 Hz, 1 H, 2eq-H), 4.06 (ddt,
J = 13.1, 4.0, 2.0 Hz, 1 H, 6eq-H), 3.58 (dd, J = 10.1, 3.5 Hz, 1 H,
7-H), 3.53 (dd, J = 10.1, 7.6 Hz, 1 H, 7-H), 2.83 (td, J = 12.9,
3.0 Hz, 1 H, 4ax-H), 2.75 (dd, J = 13.1, 11.1 Hz, 1 H, 2ax-H), 2.68
(m, 1 H, 6ax-H), 2.02 (tdt, J = 11.1, 7.6, 3.9 Hz, 1 H, 3ax-H), 1.73
(dtd, J = 13.1, 3.5, 2.5 Hz, 1 H, 5eq-H), 1.62 (qd, J = 12.6, 4.5 Hz,
1 H, 5ax-H), 1.44 (s, 9 H, 21-H) ppm. 13C NMR + DEPT 135
(100 MHz, [D6]DMSO, 353 K): δ = 160.5 (C, d, J = 241.0 Hz, C-
18), 154.3, 153.6, 147.5, 141.0 (4 C, C-19, C-8, C-10, C-12), 139.3
(C, d, J = 2.9 Hz, C-15), 128.7 (CH, d, J = 7.8 Hz, C-16), 114.7
(CH, d, J = 21.4 Hz, C-17), 107.5 (CH, C-13), 105.8 (CH, C-14),
100.5 (CH2, C-11), 97.6 (CH, C-9), 78.3 (C, C-20), 68.9 (CH2, C-
7), 46.4, 43.6 (CH2, C-2, C-6), 43.1 (CH, C-4), 40.8 (CH, C-3), 33.2
(CH2, C-5), 27.8 (CH3, C-21) ppm. 19F NMR (282 MHz, [D6]-
DMSO, 298 K): δ = –116.2 (s, 1 F) ppm.
()-Paroxetine Hydrochloride Salt (5·HCl): trans-N-Boc-4-(p-fluoro-
phenyl)-3-[3,4-(methylenedioxy)phenoxymethyl]piperidine (trans-
11; 286 mg, 0.67 mmol, 1 equiv.) was dissolved in 2-propanol
(3.3 mL). Concentrated hydrochloric acid (101 μL, 1.00 mmol,
1.5 equiv.) was added, and the solution was stirred for 5 h at 75 °C.
The resulting mixture was cooled to room temp. and concentrated
under reduced pressure. The residue was dried by azeotroping with
absolute ethanol (3 3 mL) to give 5·HCl (243 mg,  99 %) as an
off-white solid, which was recrystallised from 2-propanol.
M.p. 124–126 °C (iPrOH). 1H NMR (400 MHz, CDCl3): δ = 9.94
(br. s, 2 H, NH2), 7.22 (dd, J = 8.3, 5.3 Hz, 2 H, 16-H), 6.99 (t, J
= 8.6 Hz, 2 H, 17-H), 6.62 (d, J = 8.6 Hz, 1 H, 13-H), 6.33 (d, J =
2.5 Hz, 1 H, 9-H), 6.12 (dd, J = 8.3, 2.3 Hz, 1 H, 14-H), 5.88 (s, 2
H, 11-H), 3.63–3.83 (m, 2 H, 2-H, 6-H), 3.60 (br. dd, J = 9.6,
2.0 Hz, 1 H, 7-H), 3.48 (dd, J = 9.3, 4.8 Hz, 1 H, 7-H), 3.17 (br. t,
J = 12.4 Hz, 1 H, 2-H), 3.04 (br. t, J = 12.1 Hz, 1 H, 6-H), 2.91
(td, J = 11.9, 3.0 Hz, 1 H, 4-H), 2.68 (m, 1 H, 3-H), 2.42 (m, 1 H,
5-H), 2.03 (br. d, J = 13.6 Hz, 1 H, 5-H) ppm. 13C NMR + DEPT
135 (100 MHz, CDCl3): δ = 161.9 (d, J = 245.9 Hz, C, C-18), 153.7,
148.2, 142.1 (C, C-8, C-10, C-12), 137.0 (d, J = 2.9 Hz, C, C-15),
128.9 (d, J = 8.8 Hz, CH, C-16), 115.8 (d, J = 22.0 Hz, CH, C-17),
107.9, 105.6 (CH, C-13, C-14), 101.2 (CH2, C-11), 97.9 (CH, C-9),
67.4 (CH2, C-7), 46.8 (CH2, C-2), 44.5 (CH2, C-6), 41.7 (CH, C-
3), 39.4 (CH, C-4), 30.0 (CH2, C-5) ppm. 19F NMR (282 MHz,
CDCl3): δ = –115.2 (s, 1 F, F18) ppm. The spectra are consistent
with reported data.[20b]
Supporting Information (see footnote on the first page of this arti-
cle): General information and experimental procedures; room-tem-
perature NMR spectra of 6, 9, 10, trans-11, and 5·HCl; determi-
nation of product ratios; characterisation of all other compounds;
copies of NMR spectra of all compounds.
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